Monday, November 9, 2026

USD/EUR Is 1% Down In The Last 21 Sessions

USD/EUR Is 1% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.96% for the last 21 sessions. At 21:07 EST on Wednesday, 28 June, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 1.675% up from its 52-week low and 12.564% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.28%, a negative 0.09%, and a positive 0.35%, respectively.

USD/EUR's highest amplitude of average volatility was 0.30% (last week), 0.35% (last month), and 0.35% (last quarter), respectively.

News about

  • Eur/usd drops as likely rate hikes from ECB propel fears of longer recession in Germany. According to FXStreet on Wednesday, 28 June, "The EUR/USD pair is displaying topsy-turvy moves around 1.0950 in the Asian session. "
  • Eur/usd prepares for lagarde’s hawkish remarks at ECB forum, US data below 1.0950. According to FXStreet on Tuesday, 27 June, "Additionally, hawkish comments from the ECB official and optimism by the German bank also allow the EUR/USD bulls to keep the reins.", "On the contrary, Monday's upbeat US activity data from Dallas Fed joins the geopolitical fears emanating from Russia, due to Moscow's tactical flight exercises over the Baltic Sea, weighing on the EUR/USD pair."
  • Eur/usd forex signal: more upside as lagarde points to more hikes - 28 June 2023. According to DailyForex on Wednesday, 28 June, "The EUR/USD pair moved above the 50-period moving average while the Relative Strength Index (RSI) has moved above the neutral point of 50. ", "The EUR/USD pair continued rising after the relatively hawkish statement by Christine Lagarde, the European Central Bank (ECB) chair. "
  • Eur/usd forex signal: to retreat ahead of US consumer confidence data - 27 June 2023. According to DailyForex on Tuesday, 27 June, "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bearish viewSell the EUR/USD pair and set a take-profit at 1.0800.", "The EUR/USD exchange rate recovered modestly ahead of the upcoming American consumer confidence and the important housing data. "
  • Eur/usd technical analysis: stable performance - 27 June 2023. According to DailyForex on Tuesday, 27 June, "Stability and tight trading is what characterizes the performance of the EUR/USD currency pair since the start of trading this week, amid a bearish momentum that settles around 1.0910 at the time of writing. ", "Overall, the European single currency - the Euro - sold off heavily ahead of the weekend after S&P Global surveys warned of a deepening slowdown in key industries across the continent's major economies, but EUR/USD managed to hold on to much of its gains in June. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com